| Non-small-cell lung cancer progression after first-line chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 12057087 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Platinum-based chemotherapy is the cornerstone of care for patients with metastatic non-small-cell lung cancer (NSCLC). It provides symptom relief, improved quality of life, and prolongation of life, compared with supportive care alone. However, all patients with stage IV disease inevitably develop resistance to chemotherapy and progressive disease. Many of these patients continue to have acceptable performance status and would therefore be eligible for second-line or even third-line treatments. Unfortunately, despite an increasing number of chemotherapeutic agents (which are effective in chemo-naive NSCLC), very few have been shown to have reproducible activity in the second-line setting. Nevertheless, recent randomized clinical trials have demonstrated that single-agent docetaxel improves survival and quality of life when delivered as second-line therapy, resulting in FDA-approval for this indication. Phase II studies evaluating other new agents, delivered singly or in combination, also have reported that gemcitabine, weekly paclitaxel, and the epidermal growth factor receptor (EGFR) inhibitors are active in a subset of patients who progress after first-line platinum-based therapy. Clinical trials are imperative in identifying additional new agents and approaches that may improve outcomes in this disease. In view of the recently established role of docetaxel, ongoing randomized studies are using a common design of single-agent docetaxel versus docetaxel plus a novel investigational agent. |
| | |
Authors:
|
Primo N Lara; Derick H M Lau; David R Gandara |
Related Documents
:
|
17620767 - Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. 9345327 - The role of chemotherapy in head and neck cancer. 7743707 - Wound healing considerations in chemotherapy and radiation therapy. 23607877 - Post-therapeutic needle biopsy in patients with hepatocellular carcinoma is a useful to... 3942987 - Recurrence potential of thin primary melanomas. 22961057 - Bone recurrence after curative resection of gastric cancer. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current treatment options in oncology Volume: 3 ISSN: 1527-2729 ISO Abbreviation: Curr Treat Options Oncol Publication Date: 2002 Feb |
Date Detail:
|
Created Date: 2002-06-11 Completed Date: 2002-07-16 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 100900946 Medline TA: Curr Treat Options Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 53-8 Citation Subset: IM |
Affiliation:
|
Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects,
therapeutic use* Carcinoma, Non-Small-Cell Lung / drug therapy* Disease Progression Drug Resistance, Neoplasm Humans Lung Neoplasms / drug therapy* Palliative Care Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypopharyngeal carcinoma.
Next Document: Local complications of non-small-cell lung cancer.